BiotechTube

Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer Recurrent

Conditions

Ovarian Cancer Recurrent

Trial Timeline

Apr 15, 2025 → Mar 27, 2029

NCT ID
NCT06843447

About Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab

Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab is a phase 1/2 stage product being developed by Daiichi Sankyo for Ovarian Cancer Recurrent. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06843447. Target conditions include Ovarian Cancer Recurrent.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06843447Phase 1/2Recruiting

Competing Products

20 competing products in Ovarian Cancer Recurrent

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
33
pemetrexed + topotecanEli LillyPhase 1
33
arzoxifene hydrochlorideEli LillyPhase 2
52
LY4337713Eli LillyPhase 1
33
PrexasertibEli LillyPhase 2
52
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
44
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
52
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
52
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
41
Enzalutamide 40 MGAstellas PharmaPhase 2
52
ASP0739Astellas PharmaPhase 1/2
41
IMAB027Astellas PharmaPhase 1
33
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
52
Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection + Progesterone Soft CapsulesSun PharmaceuticalPhase 3
77
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85